March 27, 2019
Novartis nets approval for Mayzent, first oral drug to treat secondary progressive RMS
Novartis on Wednesday said that it got approval from the FDA for Mayzent for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.